Ensysce Biosciences, Inc. — Form 8-K
Filed July 15, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Ensysce Biosciences filed an 8-K on July 15, 2026, disclosing Item 5.02 (departure of directors/officers and compensatory arrangements). The filing document references these events but the specific names, titles, dollar amounts, equity grants, severance terms, and dates are not provided in the excerpt—only that the filing exists and contains Item 5.02 disclosures. No financial statements or detailed exhibits are summarized in the text provided.
Why this rating
Officer change is routine disclosure; specifics unavailable. At $5.3M market cap, impact depends on role/compensation size—unquantified here, so low-to-moderate baseline scoring applied.
Extracted items
- 5.02 exec change
- 9.01 exhibits
See more from July 15, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.